Working with the media
Welcome to the European Medicines Agency’s online media centre. This page highlights information which is of specific interest to media professionals.
The page is kept updated with news, events and information for journalists with a professional interest in the development and availability of medicines in the European Union.
For more information, please contact the EMA press office.
Press briefing: Launch of PRIME - priority medicines
Watch the recording of our press briefing on 7 March to launch the PRIME scheme, which aims to bring promising innovative medicines to patients faster by optimising and supporting medicine development.
Human medicines highlights for 2015
EMA has released an overview of its key recommendations in 2015 on the authorisation of new medicines and the safety monitoring of authorised medicines. EMA recommended 93 medicines for marketing authorisation. This includes recommendations for 39 new active substances.
Search for all press releases, news items and other media materials.
All about medicines
Search for information on medicines and browse the European database of suspected adverse drug reaction reports.
Find out more about EMA's scientific committees and working parties
Funding, statistics and key operating information
News for media professionals
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016
Eight medicines recommended for approval, including four orphan medicines ... Read more
Recommendations for patients with kidney impairment updated in product information ... Read more
Medicine should only be used with dosing syringe included in the package ... Read more
Quality of data improves as 29 countries collect and provide information ... Read more
- See all News for media professionals
Events of interest
12/09/2016 - 13/09/2016
This workshop is co-sponsored by the EMA and the Critical Path Institute. It focuses on reviewing the progress and exploring new initiatives for the International Neonatal Consortium (INC), which is dedicated to accelerating the development of safe and effective therapies for neonates. One cross-cutting topic is how to enhance a research culture. Other overarching topics are precision medicine for neonates and long-term outcome measures. Therapeutic areas that will be examined include Neonatal Abstinence Syndrome (NAS) and Necrotizing Enterocolitis (NEC). ... Read more
This forum brings together regulators with patients, healthcare professionals and industry, to take stock of what we have achieved and what needs to be the focus over the coming years. ... Read more
The European Medicines Agency is organising this workshop in collaboration with the European Commission to gather the views and proposals from stakeholders on the adaptive pathways approach, in light of the practical experience gained during the pilot project EMA ran between March 2014 and August 2016, and to plan the next steps in the exploration of this concept. Adaptive pathways is a scientific concept of medicines development and data generation intended for medicines that address patients’ unmet medical needs. ... Read more
This information day will review signal detection and management activities essential to the overall risk management process of a medicinal product. The event will explain the impact of the implementation of the 2010 pharmacovigilance legislation, with a strong focus on signal detection and management within the European Union, emphasising the requirements to be implemented in 2017. ... Read more
15/11/2016 - 16/11/2016
Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products
The CAT is organising a two day workshop to discuss the scientific developments and regulatory requirements for products manufacture and testing, non-clinical studies and clinical development of genetically modified cell-based cancer immunotherapy products. These novel cancer immunotherapy treatments based on genetically modified T-cells are being developed and tested in clinical trials in a variety of cancers, but there are still scientific and regulatory changes to overcome to bring these innovative products to the market. The workshop is available for participants from regulatory authorities, academia, hospitals, industry, journalists and interested members of the public. ... Read more
- See all Events of interest